|
1
|
Osorio JC, Andrade-Madrigal C, Gheit T, Corvalán AH, Aguayo F. SLC7A11 Expression Is Up-Regulated in HPV- and Tobacco-Associated Lung Cancer. Int J Mol Sci 2024; 25:13248. [PMID: 39769017 PMCID: PMC11676194 DOI: 10.3390/ijms252413248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2024] [Revised: 12/03/2024] [Accepted: 12/04/2024] [Indexed: 01/11/2025] Open
Abstract
High-risk human papillomaviruses (HR-HPVs) are the etiological agents of cervical, anogenital, and a subset of oropharyngeal cancers. In addition, HR-HPVs have been detected in lung carcinomas worldwide, even though the role of these viruses in this type of cancer is not fully understood. This study evaluated the presence of HPV in a cohort of 204 lung cancer cases by multiplex polymerase chain reaction (PCR)-Luminex. In addition, we used transcriptomic approaches to characterize the HPV-associated gene expression profile in the context of tobacco-smoke-associated lung cancer. HPV16 was detected in 8/204 lung carcinomas (4.0%). Through a significance analysis of microarrays (SAM) analysis, we found that the solute carrier family 7-member 11 (SLC7A11/xCT) gene (an antiporter that mediates the uptake of extracellular cystine) is up-regulated in tobacco-smoke- and HPV-associated lung cancers. In addition, SLC7A11 up-regulation correlates with both HR-HPV16 E6/E7 expression and tobacco smoke exposure in lung epithelial cells. Furthermore, we found decreased survival in HPV/SLC7A11-positive patients with lung cancer when compared to HPV/SLC7A11-negative cases. Thus, this study suggests that SLC7A11 up-regulation is associated with both HPV-positive and tobacco-smoke-associated lung carcinomas, with a potential association with clinical prognosis.
Collapse
Affiliation(s)
- Julio C. Osorio
- Laboratorio de Oncovirología, Departamento de Ciencias Biomédicas, Facultad de Medicina, Universidad de Tarapacá, Arica 1000000, Chile; (J.C.O.); (C.A.-M.)
| | - Cristian Andrade-Madrigal
- Laboratorio de Oncovirología, Departamento de Ciencias Biomédicas, Facultad de Medicina, Universidad de Tarapacá, Arica 1000000, Chile; (J.C.O.); (C.A.-M.)
| | - Tarik Gheit
- Epigenomics and Mechanisms Branch, International Agency for Research on Cancer (IARC), 69007 Lyon, France;
| | - Alejandro H. Corvalán
- Department of Hematology & Oncology and Advanced Center for Chronic Diseases (ACCDIS), Pontificia Universidad Católica de Chile, Santiago 8320000, Chile
| | - Francisco Aguayo
- Laboratorio de Oncovirología, Departamento de Ciencias Biomédicas, Facultad de Medicina, Universidad de Tarapacá, Arica 1000000, Chile; (J.C.O.); (C.A.-M.)
| |
Collapse
|
|
2
|
Sequeira T, Pinto R, Cardoso C, Almeida C, Aragão R, Almodovar T, Bicho M, Bicho MC, Bárbara C. HPV and Lung Cancer: A Systematic Review. Cancers (Basel) 2024; 16:3325. [PMID: 39409943 PMCID: PMC11475761 DOI: 10.3390/cancers16193325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2024] [Revised: 09/13/2024] [Accepted: 09/24/2024] [Indexed: 10/20/2024] Open
Abstract
This systematic review aims to explore the diagnostic criteria, epidemiology, etiology, and prognosis of Human Papillomavirus (HPV) infection in lung cancer. This PRISMA-guided review searched the PubMed® and EmbaseTM databases for "lung cancer AND HPV" on 10 June 2023, filtering human subject papers. A total of 97 studies encompassing 9098 patients worldwide, revealing varied HPV infection rates in lung cancer, ranging from 0% to 69%, were analyzed. While HPV16/18 was predominant in some regions, its association with lung cancer remained inconclusive due to conflicting findings. Studies from Asia reported lower HPV infection rates compared to Western populations. Some studies suggested a limited role of HPV in lung carcinogenesis, particularly in non-smokers. However, intriguing associations were noted, including HPV's potential role in lung adenocarcinoma and squamous cell carcinoma. Discrepancies in HPV detection methods and sample sources highlight the need for further research with standardized methodologies to elucidate HPV's role in lung carcinogenesis and its clinical implications. Overall, this systematic review offers insights into HPV's role in lung cancer epidemiology and clinical characteristics. Despite inconclusive evidence, intriguing associations between HPV and lung adenocarcinoma and squamous cell carcinoma have emerged. Further research with standardized methodologies and larger cohorts is needed for clarity.
Collapse
Affiliation(s)
- Telma Sequeira
- Serviço de Pneumologia, Instituto Português de Oncologia (IPO), Rua Lima Basto, 1099-023 Lisboa, Portugal; (C.A.); (R.A.); (T.A.)
- Laboratório Associado TERRA, Instituto de Saúde Ambiental (ISAMB), Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal; (M.C.B.); (C.B.)
| | - Rui Pinto
- Joaquim Chaves Saúde, Rua Aníbal Bettencourt, n° 3, Edifício CORE, 2790-225 Oeiras, Portugal; (R.P.); (C.C.)
| | - Carlos Cardoso
- Joaquim Chaves Saúde, Rua Aníbal Bettencourt, n° 3, Edifício CORE, 2790-225 Oeiras, Portugal; (R.P.); (C.C.)
| | - Catarina Almeida
- Serviço de Pneumologia, Instituto Português de Oncologia (IPO), Rua Lima Basto, 1099-023 Lisboa, Portugal; (C.A.); (R.A.); (T.A.)
| | - Rita Aragão
- Serviço de Pneumologia, Instituto Português de Oncologia (IPO), Rua Lima Basto, 1099-023 Lisboa, Portugal; (C.A.); (R.A.); (T.A.)
| | - Teresa Almodovar
- Serviço de Pneumologia, Instituto Português de Oncologia (IPO), Rua Lima Basto, 1099-023 Lisboa, Portugal; (C.A.); (R.A.); (T.A.)
| | - Manuel Bicho
- Instituto de Investigação Científica Bento da Rocha Cabral, Calçada Bento da Rocha Cabral 14, 1250-012 Lisboa, Portugal;
| | - Maria Clara Bicho
- Laboratório Associado TERRA, Instituto de Saúde Ambiental (ISAMB), Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal; (M.C.B.); (C.B.)
| | - Cristina Bárbara
- Laboratório Associado TERRA, Instituto de Saúde Ambiental (ISAMB), Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal; (M.C.B.); (C.B.)
- Unidade Local de Saúde de Santa Maria, Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal
| |
Collapse
|
|
3
|
Alikanoğlu AS, Karaçay İA. Detection of High-Risk Human Papillomavirus (HPV), p16 and EGFR in Lung Cancer: Insights from the Mediterranean Region of Turkey. Viruses 2024; 16:1201. [PMID: 39205175 PMCID: PMC11360564 DOI: 10.3390/v16081201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Revised: 07/15/2024] [Accepted: 07/23/2024] [Indexed: 09/04/2024] Open
Abstract
Human papillomavirus (HPV) is an oncogenic DNA virus that plays a role in different cancer types. The aim of this study was to detect the prevalence and types of HPV and its relation with p16, EGFR and clinical findings in lung cancer. HPV and EGFR detection and genotyping of HPV were performed by polymerase chain reaction (PCR) and p16 by immunohistochemistry. Fifty lung cancer patients and seven patients with non-neoplastic lung disease were enrolled in this study. HPV was positive in 78% (39/50) of lung cancer cases. HPV 51 was the most frequent type, followed by HPV 16. Moreover, p16 was positive in 24% (12/50) of the cancer patients, and all of these patients were HPV-positive, while 27 HPV-positive patients showed no p16 expression. There was no relationship between HPV infection and p16 (p = 0.05), gender (p = 0.42), age (p = 0.38), or smoking history (p = 0.68). Although not statistically significant, the HPV prevalence was found to be higher in cancer patients compared to non-neoplastic patients. The prevalence of HPV in lung cancer varies across different studies, which may be due to differences in the detection methods, number of patients, geographic regions, and vaccination status. Further studies are necessary to understand the role of HPV in lung cancer pathogenesis.
Collapse
Affiliation(s)
- Arsenal Sezgin Alikanoğlu
- Pathology Department, Antalya Education and Research Hospital, Health Sciences University, Antalya 07100, Turkey
| | - İrem Atalay Karaçay
- Pathology Department, Alanya Alaaddin Keykubat University, Antalya 07400, Turkey
| |
Collapse
|
|
4
|
Nachira D, Congedo MT, D’Argento E, Meacci E, Evangelista J, Sassorossi C, Calabrese G, Nocera A, Kuzmych K, Santangelo R, Rindi G, Margaritora S. The Role of Human Papilloma Virus (HPV) in Primary Lung Cancer Development: State of the Art and Future Perspectives. Life (Basel) 2024; 14:110. [PMID: 38255725 PMCID: PMC10817459 DOI: 10.3390/life14010110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 12/29/2023] [Accepted: 01/05/2024] [Indexed: 01/24/2024] Open
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Notably, the incidence of lung cancer among never-smokers, predominantly women, has been rising in recent years. Among the various implicated risk factors, human papilloma virus (HPV) may play a role in the development of NSCLC in a certain subset of patients. The prevalence of high-risk HPV-DNA within human neoplastic lung cells varies across the world; however, the carcinogenetic role of HPV in NSCLC has not been completely understood. Bloodstream could be one of the routes of transmission from infected sites to the lungs, along with oral (through unprotected oral sex) and airborne transmission. Previous studies reported an elevated risk of NSCLC in patients with prior HPV-related tumors, such as cervical, laryngeal, or oropharyngeal cancer, with better prognosis for HPV-positive lung cancers compared to negative forms. On the other hand, 16% of NSCLC patients present circulating HPV-DNA in peripheral blood along with miRNAs expression. Typically, these patients have a poorly differentiated NSCLC, often diagnosed at an advanced stage. However, HPV-positive lung cancers seem to have a better response to target therapies (EGFR) and immune checkpoint inhibitors and show an increased sensitivity to platinum-based treatments. This review summarizes the current evidence regarding the role of HPV in NSCLC development, especially among patients with a history of HPV-related cancers. It also examines the diagnostic and prognostic significance of HPV, investigating new future perspectives to enhance cancer screening, diagnostic protocols, and the development of more targeted therapies tailored to specific cohorts of NSCLC patients with confirmed HPV infection.
Collapse
Affiliation(s)
- Dania Nachira
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| | - Maria Teresa Congedo
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| | - Ettore D’Argento
- Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy;
| | - Elisa Meacci
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| | - Jessica Evangelista
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| | - Carolina Sassorossi
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| | - Giuseppe Calabrese
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| | - Adriana Nocera
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| | - Khrystyna Kuzmych
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| | - Rosaria Santangelo
- Institute of Microbiology, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy;
| | - Guido Rindi
- Institute of Pathology, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy;
| | - Stefano Margaritora
- Department of General Thoracic Surgery, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (M.T.C.); (E.M.); (J.E.); (C.S.); (G.C.); (A.N.); (K.K.); (S.M.)
| |
Collapse
|